Cotrimoxazole Prophylaxis in Transurethral Resection or Greenlight Laser Vaporisation of the Prostate (CITrUS)
Antimicrobial Prophylaxis in Prostate Surgery

About this trial
This is an interventional treatment trial for Antimicrobial Prophylaxis in Prostate Surgery focused on measuring Greenlight Laser Vaporisation of the Prostate, Transurethral resection of the prostate, Cotrimoxazole Prophylaxis
Eligibility Criteria
Inclusion Criteria:
- Obstructive voiding disorder (e.g. benign prostate hyperplasia, obstructive prostate cancer)
- Planned Transurethral resection of the prostate (TURP) or Greenlight Laser (GL)
Exclusion Criteria:
- Evidence for (catheter associated-) UTI, with or without antibiotic treatment in the last 7 days prior to randomisation.
- Any evidence of a history of positive urine culture (cfu ³105/ml in midstream-urine with no more than two species) and resistance to TMP/SMX in the last 7 days prior to randomisation.
- Known contraindication against study drugs according to the Swissmedic package leaflet (e.g. known liver dysfunction, renal insufficiency; patients with glomerular filtration rate (calculated by the Modification of Diet in Renal Disease (MDRD) or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <30ml/min or dialysis patients will be excluded).
- Antibiotic treatment for any reason within 7 days prior to randomisation
- Indication for Antibiotic prophylaxis (AP) for other reasons (e.g. endocarditis prophylaxis, transplanted patients under systemic immunosuppression).
Sites / Locations
- St. Claraspital, Department of UrologyRecruiting
- Kantonsspital Aarau, Department of UrologyRecruiting
- University Hospital Basel, Division of Infectious Diseases and Hospital EpidemiologyRecruiting
- Kantonsspital Baselland, Department of UrologyRecruiting
- University Hospital Zurich, Department of Urology
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
Group A
Group B
Single-dose Trimethoprim (TMP)/sulfamethoxazole (SMX, i.e. Cotrimoxazole) perioperative as two ampoules of TMP/SMX 400/80 mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion followed by five oral applications of placebo (lactose tablet; Fagron Gesellschaft mit beschränkter Haftung (GmbH) & Co.KG) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
3-day application with TMP/SMX (i.e. Cotrimoxazole): Preoperatively as two ampoules of TMP/SMX 400/80mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion, followed by five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.